Shares of Heron Therapeutics Inc. (NASDAQ:HRTX) shot up 4.9% on Friday . The company traded as high as $17.45 and last traded at $17.25, with a volume of 319,375 shares. The stock had previously closed at $16.44.

A number of research firms have recently weighed in on HRTX. Cowen and Company restated a “buy” rating on shares of Heron Therapeutics in a report on Saturday, July 9th. Leerink Swann reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Monday, June 27th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $41.00 price target on shares of Heron Therapeutics in a research note on Friday, June 24th. Brean Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Heron Therapeutics in a research note on Friday, May 6th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, April 28th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $51.50.

The firm has a 50 day moving average of $18.61 and a 200 day moving average of $19.75.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.92). Equities research analysts anticipate that Heron Therapeutics Inc. will post ($3.59) EPS for the current fiscal year.

In other news, President Robert Rosen sold 200,000 shares of the stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $23.23, for a total value of $4,646,000.00. Following the completion of the sale, the president now directly owns 178,968 shares in the company, valued at $4,157,426.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Several large investors have modified their holdings of HRTX. Swiss National Bank acquired a new stake in shares of Heron Therapeutics during the fourth quarter worth approximately $1,100,000. GAM Holding AG boosted its stake in shares of Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock worth $1,119,000 after buying an additional 9,400 shares during the period. Russell Frank Co boosted its stake in Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock valued at $1,369,000 after buying an additional 15,585 shares during the last quarter. California State Teachers Retirement System boosted its stake in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 1,000 shares during the last quarter. Finally, Oxford Asset Management purchased a new stake in Heron Therapeutics during the fourth quarter valued at about $2,210,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.